Page last updated: 2024-09-05

sb 203580 and Adenocarcinoma Of Kidney

sb 203580 has been researched along with Adenocarcinoma Of Kidney in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chauhan, A; Mishra, SP; Ojha, R; Semwal, DK; Semwal, RB	1

Other Studies

1 other study(ies) available for sb 203580 and Adenocarcinoma Of Kidney

Article	Year
Combined Treatment with CCI779 and SB203580 Induces Cellular Senescence in Renal Cell Carcinoma Cell Line via p53 Pathway. Anti-cancer agents in medicinal chemistry, 2017, Nov-24, Volume: 17, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imidazoles; Kidney Neoplasms; Molecular Structure; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridines; Sirolimus; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2017

Article

Year

Combined Treatment with CCI779 and SB203580 Induces Cellular Senescence in Renal Cell Carcinoma Cell Line via p53 Pathway.

Anti-cancer agents in medicinal chemistry, 2017, Nov-24, Volume: 17, Issue:11

Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imidazoles; Kidney Neoplasms; Molecular Structure; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridines; Sirolimus; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2017